Home › Stocks › Pharma & healthcare stocks › Zydus Lifesciences
Pharma & healthcare stocks Valuation research

Zydus Lifesciences fair value — generics, India and wellness

Zydus, once Cadila Healthcare, combines US generics, Indian prescription brands and consumer products like Complan and Glucon-D. The valuation asks how lasting its recent margin gains are.

FairStocks Research
Updated 16 Nov 2026 · 4 min read
| NSE: ZYDUSLIFE ₹1,192
On this page ▾
  1. The business
  2. What the market assumes
  3. The ten-year record
  4. How it is valued
  5. What decides the value
  6. What could go wrong
  7. The full valuation
  8. Compare with peers
  9. Questions
Zydus Lifesciences (ZYDUSLIFE) fair value — is it overvalued? Price ₹1,192, P/E 28.5, P/B 4.39, ROE —. Based on 10 years of reported financials. FairStocks.
Zydus Lifesciences at a glance. Share price, P/E, P/B and the ten-year revenue trend, from filed accounts. Updated 16 Nov 2026.
In 30 seconds

The market expects much less from Zydus Lifesciences than it has delivered before.

At today’s share price, buyers are assuming Zydus Lifesciences grows about 0% a year, forever. Over the last ten years it actually grew about 15% a year. That is a big step down from its own record — in other words, that it stops growing altogether. Either the market can see a problem that the published accounts do not show yet, or it is expecting a slowdown that has not happened.

  • How it is valued: Discounted cash flow.
  • What the price assumes: 0% growth, against 15% the model takes from its own record.
  • Ten-year record: Between FY2018 and FY2026, Zydus Lifesciences' revenue went from ₹11,936 crore to ₹27,148 crore — it compounded at about 11% a year over 8 years.
  • Biggest swing factor: US launches. Main risk: FDA inspections.
Price
₹1,192
Market cap
₹1.19L Cr
P/E
28.5
P/B
4.39
See Zydus' fair value and the full DCFEvery step of the Zydus Lifesciences working, the scenarios and the report Free during launch →

01From Cadila Healthcare to Zydus

Zydus Lifesciences, based in Ahmedabad and renamed from Cadila Healthcare in 2022, is one of India's larger drugmakers. It sells generic medicines in the US, branded prescriptions in India and has a growing pipeline of specialty and biological products.

Through Zydus Wellness it also owns consumer brands such as Complan, Glucon-D, Sugar Free and Nycil, which adds a non-prescription business to the group.

02What the market is assuming

Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Zydus Lifesciences, next to what the model assumes from the company's own record.

Market expects
0%
growth priced into today's price
Model assumes
15%
growth the model assumes

The further apart these two numbers are, the bigger the bet a buyer at today's price is making.

03Zydus Lifesciences' record, in plain numbers

Between FY2018 and FY2026, Zydus Lifesciences' revenue went from ₹11,936 crore to ₹27,148 crore — it compounded at about 11% a year over 8 years. Net profit grew from ₹1,810 crore to ₹5,124 crore, about 14% a year — faster than revenue, so margins widened. In FY2026 it kept 18.9% of revenue as net profit — against a low of 8.5% in FY2020 and a high of 30.3% in FY2022. The latest year added 16.8% to revenue, well ahead of its own long-run pace.

Reading the record. FY2022 profit was lifted by the one-time gain from selling the animal-health business; FY2023 is the cleaner comparison.
Revenue₹0.12L → ₹0.27L Cr
181920212223242526
Earnings per share₹17.4 → ₹50.1
181920212223242526
Return on equity20.1% → 37.9%
19202122232426

Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.

Revenue and net profit by year (₹ crore)
YearRevenueNet profitMargin
FY201811,9361,81015.2%
FY201913,1661,89914.4%
FY202014,2531,2048.5%
FY202115,1022,18514.5%
FY202215,2654,61830.3%
FY202317,2372,09212.1%
FY202419,5473,97320.3%
FY202523,2424,67320.1%
FY202627,1485,12418.9%

04How Zydus Lifesciences gets valued — and why

Discounted cash flow

This business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.

05What decides Zydus Lifesciences' value

US launches

New and complex generics drive US growth.

India brands

Steady domestic prescriptions support cash flow.

Specialty pipeline

Novel products could add higher-margin revenue.

Consumer wellness

Seasonal brands add diversification.

06What could go wrong

  • FDA inspections. Adverse findings can block US approvals.
  • US price erosion. Generic prices fall as competitors enter.
  • Pipeline setbacks. Failed trials remove expected growth.

07What the full Zydus valuation shows

Model value per share
₹0,000
Upside
+00%
Call
XXXX

Sign in free to see the complete Zydus Lifesciences valuation

  • ✓Fair value per share — from a ten-year discounted cash flow, every step shown
  • ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Zydus' value move
  • ✓Bull, base and bear cases — and exactly which assumptions move between them
  • ✓Peer comparison — against Sun Pharma, Dr Reddy's and Lupin
  • ✓Downloadable report — the full write-up, yours to keep
See Zydus' fair value and the full DCF — free
Free during launch · unlimited valuations · no card required

08Compare Zydus Lifesciences with peers

The same valuation, run side by side.

Zydus Lifesciences vs Sun PharmaA mid-large generics maker against the sector leader.→Zydus Lifesciences vs Dr Reddy'sThe nearest peer on US-generics exposure.→Zydus Lifesciences vs LupinTwo generics books at similar scale.→

09Questions people ask about Zydus Lifesciences

Is Zydus Lifesciences the same as Cadila Healthcare?

Yes. Cadila Healthcare renamed itself Zydus Lifesciences in 2022.

What consumer brands does Zydus own?

Through Zydus Wellness: Complan, Glucon-D, Sugar Free, Nycil and others.

Zydus or Lupin — which is better value?

Two generics makers at similar scale, compared side by side on their own page.

Is Zydus Lifesciences overvalued?

At ₹1,192 the market is pricing in roughly 0% sustained growth, against the ~15% its own record supports. That is less than it has delivered — on these numbers the market is asking the business for less than its own record, which usually means it doubts the record repeats.

What is the intrinsic value of Zydus Lifesciences?

It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.

How much debt does Zydus Lifesciences carry?

Debt to equity stands at 0.12, against 0.00 at the start of the period — the balance sheet is a core input to the cost of capital used here.

About this research

Written by the FairStocks research team from Zydus Lifesciences' filed accounts and last reviewed 5 Oct 2026; the figures refresh as new results are filed. Every valuation uses the method that fits the business and shows its assumptions — see a fully worked example or the valuation guides. Educational research, not investment advice.

See Zydus' fair value and the full DCFUnlock free